Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly and Company (LLY) Management Presents at Citi's 16th Annual BioPharma Virtual Conference (Transcript)

INDIANAPOLIS, Sept. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the pricing of its first sustainability bond to advance its global environmental, social and governance (ESG) strategy to increase access to medicines, improve lives and communities, empower a diverse workforce, minimize environmental impact and operate ethically and responsibly.

Lilly Prices First Sustainability Bond to Advance Global ESG Strategy

INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)

Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)

RIDGEFIELD, Conn. and INDIANAPOLIS, Sept.

FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction

Eli Lilly And Co (NYSE: LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing player focused on neuroscience, ProQR Therapeutics N.V. (NASDAQ: PRQR).

Eli Lilly Inks Another RNA Collab, This Time With ProQR

INDIANAPOLIS, Sept. 7, 2021 /PRNewswire/ -- Lilly Diabetes will commit nearly $1 million over the next three years in a joint effort with The Leona M.

Lilly Diabetes joins The Leona M. and Harry B.

INDIANAPOLIS, Sept. 7, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $1.5 billion combined aggregate principal amount (the "Tender Cap") of specified series of its outstanding debt securities.

Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities

Ameriprise Financial

Blackrock Inc

Carlyle Group

CNH Industrial NV

Garmin

Infosys

KLA-Tencor

T. Rowe Price Group

Taiwan Semiconductor Manufacturing

United Microelectronics

Vici Properties

Releasing two top September stocks from the MDA Growth and Dividend Breakout portfolio and two top samples from prior portfolios. Long-term dividend portfolios have a 1-year average weighted gain of +29.42%. The best gain is from the May 2020 portfolio, +89.2%.

V&M Breakouts: Top Growth And Dividend Stocks For September 2021

INDIANAPOLIS, Sept. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021.

Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Why Is Lilly (LLY) Down 1.9% Since Last Earnings Report?

AbbVie

Pfizer

The FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz/Xeljanz XR, Lilly (LLY)/Incyte's (INCY) Olumiant, and AbbVie's (ABBV) Rinvoq.

FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels

INDIANAPOLIS , Aug. 31, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will participate in Citi's 16th Annual BioPharma Virtual Conference on September 8 and 9, 2021. Anat Ashkenazi, senior vice president and chief financial officer, will participate in a virtual fireside chat on Thursday, September 9 at 9:45 a.m.

Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference

AstraZeneca

Biogen

Clovis Oncology

Denali Therapeutics

Morphosys AG - ADR

Clovis Oncology Inc. ( CLVS , Financial) and Denali Therapeutics Inc. ( DNLI , Financial) are among the most likely biotechs to be acquired, according to industry publications. Denali, by far, would be the most expensive of the pair with a market cap of $6.4 billion, while Clovis is far more digestible with a market value of only $567 million.

Biotech Takeovers Moved at Snail's Pace in 2nd Quarter

After the US paused distribution of Eli Lilly And Co (NYSE: LLY)'s COVID-19 antibody therapies in June, the pharmaceutical company says those therapies are once again being distributed. What happened: Eli Lilly has announced that the Office of the Assistant Secretary for Preparedness and Response, alongside the U.S. Food and Drug Administration, has resumed the shipment and distribution of bamlanivimab and etesevimab administered together.

Distribution Resumes Of Eli Lilly COVID-19 Antibody Therapies

The pharmaceutical company's type 2 diabetes drug Jardiance was recently approved by the FDA for another indication.

Here's What This Label Expansion Could Mean for Eli Lilly Investors

SHANGHAI, China, Aug. 29, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (the “FDA”), alongside the Office of the Assistant Secretary for Preparedness and Response, has resumed the shipment and distribution of etesevimab and bamlanivimab administered together (the “Therapy”), according to the company's global partner Eli Lilly and Company (NYSE: LLY). Direct ordering will be available to authorized states in the U.S. effective immediately.

Distribution of Etesevimab/JS016 in the US Reopened

Eli Lilly And Co (NYSE: LLY) and Boehringer Ingelheim have rolled out full results of EMPEROR-Preserved phase 3 trial of Jardiance (empagliflozin) for heart failure with preserved ejection fraction (HFpEF).  The data was delivered at the annual meeting of the European Society of Cardiology (ESC).

Eli Lilly, Boehringer Share Jardiance Data In Heart Failure Field

INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in adults with HFpEF

Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 27, 2021 /PRNewswire/ -- Full results from the landmark EMPEROR-Preserved phase III trial demonstrated that Jardiance® (empagliflozin) showed an impressive 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction (HFpEF) compared with placebo.

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Eli Lilly updated investors on its ongoing phase 3 trials to treat patients who have moderate to severe eczema with a new drug.

This Potential Indication Could Mean Profit for Eli Lilly Investors

INDIANAPOLIS, Aug. 25, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) announced today that Carolyn R. Bertozzi, Ph.D.

Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Aug. 25, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.

Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders

Novo Nordisk

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)

Sanofi

House Energy & Commerce Committee leaders sent three letters to execs at Eli Lilly And Co (NYSE: LLY), Sanofi SA (NASDAQ: SNY), and Novo Nordisk A/S (NYSE: NVO), raising concerns that despite their supposed concern over the past two years with the price of insulin, the price still remains "unacceptably high." Committee chair Frank Pallone (D-NJ) and subcommittee chair Diana DeGette (D-CO) note in all three letters that the price of insulin in the U.S. is more than 10 times that of 33 other countries.

House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices

Lilly's (LLY) Jardiance gets FDA approval for heart failure with reduced ejection fraction (HFrEF), based on data from the phase III EMPEROR-Reduced study

News for Eli Lilly Stock (LLY)